Telix QSAM Inc (QSAM)

[Televet]

QSAM Biosciences, Inc. – Follow-On Offering



Issuer:

QSAM Biosciences, Inc.

Listing:

Current Listing: OTCQB: QSAMD

Listing on Nasdaq under the ticker symbol: QSAM

Expected Offering Size:

Approximately $20,000,000

Over-Allotment Option:

15% (100% Primary)

Expected Timing

March 24th

Sole Book-Runner:

ThinkEquity

Business Summary:

QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. The Company’s initial technology is Samarium-153 DOTMP, a/k/a CycloSam® (“CycloSam®” or the “New Technology”), a clinical-stage bone targeting radiopharmaceutical. CycloSam® features a patented, low specific activity form of Samarium-153, a beta-emitting radioisotope with a short 46-hour half-life, and the chelating agent DOTMP, which selectively targets sites of high bone mineral turnover and reduces off-site migration of the tumor-killing radiation.







Link to Preliminary Prospectus Supplement, filed with the SEC on March 10, 2022: https://www.sec.gov/ix?doc=/Archives/edgar/data/1310527/000149315222006465/forms-1a.htm